Payment overview · 2025
General Payments
$445.60
23 reported records · 11 companies
Healthcare provider profile · identity verified
Randy James Daigle, MD
Allopathic & Osteopathic Physicians|Family Medicine · SUNSET, LA · NPI 1558361865
Verified facts
What the public records show
CMS Open Payments records show Randy James Daigle, MD received $445.60 in general payments during 2025 across 23 reported records.
ABBVIE INC. accounted for 20.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $89.57 | 20.1% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $67.09 | 15.1% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $56.75 | 12.7% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $49.27 | 11.1% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $43.71 | 9.8% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $32.84 | 7.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.03 | 7.2% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.03 | 4.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.01 | 4.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.61 | 4.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.69 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $445.60 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $67.09 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $67.09 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $56.75 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $50.42 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $43.71 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $39.15 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $32.84 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.03 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $32.03 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $29.55 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $20.03 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $20.01 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.01 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.01 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.61 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 81 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 159 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
39 | 14 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
68 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
81 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
159 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
185 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
25 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 923 | 147 |
| Alprazolam | Alprazolam | 833 | 103 |
| Levothyroxine Sodium | Levothyroxine Sodium | 816 | 127 |
| Atorvastatin Calcium | Atorvastatin Calcium | 784 | 146 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 655 | 112 |
| Metformin Hcl | Metformin Hcl | 652 | 121 |
| Losartan Potassium | Losartan Potassium | 643 | 111 |
| Omeprazole | Omeprazole | 632 | 103 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 610 | 92 |
| Lisinopril | Lisinopril | 560 | 102 |
| Gabapentin | Gabapentin | 530 | 93 |
| Pantoprazole Sodium | Pantoprazole Sodium | 517 | 87 |
| Tramadol Hcl | Tramadol Hcl | 440 | 70 |
| Hydrochlorothiazide | Hydrochlorothiazide | 426 | 77 |
| Potassium Chloride | Potassium Chloride | 338 | 56 |
| Furosemide | Furosemide | 333 | 80 |
| Meloxicam | Meloxicam | 322 | 66 |
| Carvedilol | Carvedilol | 311 | 63 |
| Montelukast Sodium | Montelukast Sodium | 282 | 46 |
| Quetiapine Fumarate | Quetiapine Fumarate | 268 | 38 |
| Glimepiride | Glimepiride | 258 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 253 | 52 |
| Buspirone Hcl | Buspirone Hcl | 239 | 48 |
| Simvastatin | Simvastatin | 237 | 38 |
| Clonazepam | Clonazepam | 230 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 228 | 29 |
| Famotidine | Famotidine | 218 | 42 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 215 | 31 |
| Amitriptyline Hcl | Amitriptyline Hcl | 208 | 40 |
| Allopurinol | Allopurinol | 202 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 198 | 35 |
| Mirtazapine | Mirtazapine | 198 | 31 |
| Alendronate Sodium | Alendronate Sodium | 196 | 35 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 195 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 194 | 31 |
| Memantine Hcl | Memantine Hcl | 194 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 194 | 34 |
| Trazodone Hcl | Trazodone Hcl | 191 | 32 |
| Doxazosin Mesylate | Doxazosin Mesylate | 190 | 32 |
| Sertraline Hcl | Sertraline Hcl | 187 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 185 | 48 |
| Eliquis | Apixaban | 185 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 173 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 169 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 167 | 37 |
| Hydralazine Hcl | Hydralazine Hcl | 164 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 160 | 30 |
| Ozempic | Semaglutide | 159 | 22 |
| Azithromycin | Azithromycin | 158 | 123 |
| Lovastatin | Lovastatin | 149 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 147 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 146 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 138 | 26 |
| Diazepam | Diazepam | 136 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 134 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 131 | 35 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 119 | 23 |
| Pregabalin | Pregabalin | 116 | 22 |
| Clonidine Hcl | Clonidine Hcl | 108 | 20 |
| Benazepril Hcl | Benazepril Hcl | 104 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 104 | 21 |
| Celecoxib | Celecoxib | 102 | 17 |
| Nebivolol Hcl | Nebivolol Hcl | 101 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 99 | 16 |
| Levofloxacin | Levofloxacin | 98 | 82 |
| Zolpidem Tartrate | Zolpidem Tartrate | 96 | 16 |
| Finasteride | Finasteride | 94 | 14 |
| Spironolactone | Spironolactone | 93 | 15 |
| Fluconazole | Fluconazole | 91 | 59 |
| Citalopram Hbr | Citalopram Hydrobromide | 89 | 14 |
| Meclizine Hcl | Meclizine Hcl | 89 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 88 | 73 |
| Atenolol | Atenolol | 86 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 85 | 70 |
| Fenofibrate | Fenofibrate | 83 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 81 | 14 |
| Jardiance | Empagliflozin | 81 | 15 |
| Acarbose | Acarbose | 80 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 80 | suppressed |
| Irbesartan | Irbesartan | 79 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 77 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 77 | 47 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 73 | 13 |
| Valsartan | Valsartan | 73 | 17 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 72 | suppressed |
| Topiramate | Topiramate | 71 | 11 |
| Ezetimibe | Ezetimibe | 70 | suppressed |
| Synthroid | Levothyroxine Sodium | 68 | suppressed |
| Ondansetron Odt | Ondansetron | 67 | 36 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 66 | 13 |
| Glipizide Er | Glipizide | 66 | 11 |
| Nifedipine Er | Nifedipine | 66 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 65 | 12 |
| Ipratropium Bromide | Ipratropium Bromide | 64 | 18 |
| Januvia | Sitagliptin Phosphate | 63 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 61 | 26 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 12 |
| Amoxicillin | Amoxicillin | 58 | 45 |
| Baclofen | Baclofen | 58 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 57 | 29 |
| Prednisone | Prednisone | 57 | 50 |
| Donepezil Hcl | Donepezil Hcl | 55 | suppressed |
| Mupirocin | Mupirocin | 54 | 32 |
| Cefdinir | Cefdinir | 53 | 48 |
| Estradiol | Estradiol | 53 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 52 | suppressed |
| Xarelto | Rivaroxaban | 52 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 51 | 12 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 49 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 19 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 46 | suppressed |
| Mounjaro | Tirzepatide | 46 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 45 | suppressed |
| Carbamazepine | Carbamazepine | 44 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 44 | 15 |
| Lorazepam | Lorazepam | 44 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 42 | suppressed |
| Belsomra | Suvorexant | 42 | suppressed |
| Levetiracetam | Levetiracetam | 42 | suppressed |
| Colchicine | Colchicine | 41 | 15 |
| Doxepin Hcl | Doxepin Hcl | 41 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 41 | suppressed |
| Temazepam | Temazepam | 41 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 11 |
| Nystatin | Nystatin | 40 | 20 |
| Carisoprodol | Carisoprodol | 39 | suppressed |
| Dexamethasone | Dexamethasone | 39 | 35 |
| Linzess | Linaclotide | 39 | 14 |
| Bupropion Xl | Bupropion Hcl | 36 | suppressed |
| Glyburide | Glyburide | 36 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 36 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 35 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 35 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | suppressed |
| Ibu | Ibuprofen | 35 | suppressed |
| Ramipril | Ramipril | 34 | suppressed |
| Aripiprazole | Aripiprazole | 31 | suppressed |
| Premarin | Estrogens, Conjugated | 31 | suppressed |
| Armour Thyroid | Thyroid,pork | 30 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | suppressed |
| Lactulose | Lactulose | 30 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Phenobarbital | Phenobarbital | 30 | suppressed |
| Hydrocortisone | Hydrocortisone | 29 | 13 |
| Nortriptyline Hcl | Nortriptyline Hcl | 29 | suppressed |
| Digoxin | Digoxin | 28 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 28 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 27 | suppressed |
| Gemfibrozil | Gemfibrozil | 27 | suppressed |
| Torsemide | Torsemide | 27 | suppressed |
| Cilostazol | Cilostazol | 26 | suppressed |
| Desloratadine | Desloratadine | 26 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 26 | suppressed |
| Vascepa | Icosapent Ethyl | 26 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 25 |
| Divalproex Sodium | Divalproex Sodium | 24 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Methocarbamol | Methocarbamol | 24 | 18 |
| Trulicity | Dulaglutide | 24 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 24 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Zonisamide | Zonisamide | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 22 | suppressed |
| Metronidazole | Metronidazole | 22 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Risperidone | Risperidone | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 19 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 21 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Sotalol | Sotalol Hcl | 21 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 19 | 17 |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 18 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 18 | suppressed |
| Lubiprostone | Lubiprostone | 18 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 18 | 16 |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | 14 |
| Ibandronate Sodium | Ibandronate Sodium | 17 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Cefadroxil | Cefadroxil | 15 | 15 |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Zafirlukast | Zafirlukast | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 12 | 12 |
| Perphenazine | Perphenazine | 12 | suppressed |
| Veozah | Fezolinetant | 12 | suppressed |
| Victoza 3-Pak | Liraglutide | 12 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Anastrozole | Anastrozole | 11 | suppressed |
| Aristada | Aripiprazole Lauroxil | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $445.60 · 23 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, Cologuard Collection Kit, JARDIANCE, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, VRAYLAR, XIFAXAN, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error